诺和诺德（NVO）在发布2025年第一季度财报后，夜盘股价大涨5.07%，引发市场广泛关注。尽管公司下调了全年预期，但投资者似乎更关注其强劲的季度业绩和新药研发进展。
根据财报显示，诺和诺德第一季度销售额以丹麦克朗计算增长19%，达到781亿丹麦克朗；营业利润增长22%，达到388亿丹麦克朗。虽然减肥药Wegovy的销售额173.6亿丹麦克朗低于市场预期，但糖尿病药物Ozempic的销售额327.2亿丹麦克朗超出预期。
此外，公司还宣布了多项新药研发进展。REDEFINE 2试验中，新药CagriSema在肥胖或超重伴2型糖尿病的成年人中显示出15.7%的卓越减肥效果。公司还已向美国FDA提交了口服司美格鲁肽25mg用于肥胖症治疗的申请，以及每周一次的司美格鲁肽2.4mg用于MASH（代谢相关性脂肪性肝炎）治疗的申请。这些积极的研发进展可能增强了投资者对公司长期增长前景的信心，推动了股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.